Aims of the study: The aim of this double-blind, randomised, prospective, multicentre trial was to evaluate the ecacy of propiverine in patients suering from detrusor hyperre¯exia caused by spinal cord injury in comparison to placebo. Study design: The treatment period of 14 days comprised visits at baseline (V1) and after 14 days treatment (V2). Fifteen mg propiverine t.i.d. or placebo t.i.d. were administered as medication. The following ecacy parameters were adopted: the urodynamic parameters maximal cystometric bladder capacity, bladder volume on onset of the ®rst as well as duration and amplitude of the maximum detrusor contraction, bladder compliance and residual urine, and subjective assessment of ecacy by physicians. For the evaluation of the safety of propiverine the incidence rate of adverse events by directly questioning as well as laboratory parameters were investigated. For biometrical evaluation t-test for independent groups was applied. Results: One hundred and thirteen patients were investigated. The maximal cystometric bladder capacity increased signi®cantly in the propiverine group, on average by 104 ml (V1: 262+132 ml. V2: 366+143 ml, P50.001). The changes in bladder capacity during the ®rst contraction and the maximum detrusor contraction in the verum group were both statistically signi®cant. The bladder compliance documented a more pronounced increase under propiverine in comparison to placebo. Residual urine increased by 37+71 ml in the propiverine group, signi®cantly more than in the placebo group (P=0.01). Sixty-three per cent of the patients expressed subjectively an improvement under propiverine in comparison with 23% of the placebo group. Expected anticholinergic adverse events occurred: dryness of the mouth (37% in the verum and 8% in the placebo group), accommodation disorders (28% and 2% respectively). Nausea, constipation, headache, dizziness, tiredness and palpitations were reported in almost comparable incidence rates between 3 and 13% in both treatment groups.
Introduction
Propiverine hydrochloride (propiverine) is a spasmolytic agent (Apogepha, pharmaceutical factory, Dresden, Germany). Due to its dual mode of action ± anticholinergic and calcium-antagonistic eect on the smooth muscles ± propiverine should have a powerful eect on the hyperre¯exive detrusor.
The pharmacologic pro®le of propiverine has been extensively studied 15, 16 . In vitro and in vivo studies revealed competitive anticholinergic properties of propiverine in comparison to atropine and oxybutynin, the calcium-antagonism is documented in several studies, eg in comparison to nifedipine. 1 ± 3 In numerous clinical trials propiverine has proved to be an eective drug in urinary incontinence due to detrusor overactivity with a moderate incidence of adverse events. 4 ± 7 Following dose optimizing clinical trials, 7 the aim of this study was the proof of ecacy and safety of propiverine in patients suering from detrusor hyperre¯exia in comparison to placebo.
Materials and methods
One hundred and thirteen patients were randomised to the propiverine group (60 patients) or to the placebo group (53 patients). Inclusion criteria were in-patients over 18 years of age suering from detrusor hyperre¯exia and suprasacral spinal cord injury. Exclusion criteria were pregnancy, cardiac, hepatic and renal dysfunctions, if requiring medical intervention, intestinal and urogenital obstructions, narrow angle glaucoma, severe psychotics and acute infections of the urinary tract.
In this double-blind, randomised, prospective, multicenter clinical trial treatment results of propiverine and placebo were compared in a parallel group design. The study was performed in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. Patient's informed consent was given. Fifteen mg propiverine (sugar-coated tablets, registered as Mictonorm 1 in Germany or Detrunorm 1 in other European countries; manufactured and supplied by Apogepha Arzneimittel GmbH, Dresden, Germany) or sugar coated placebo tablets were administered t.i.d. for 14 days. Apogepha supported the study by an educational grant.
Evaluation of ecacy and safety comprised two visits (V1 ± day 0, V2 ± day 14): (1) 
Results
Four study centres recruited 113 patients (69 men and 44 women). Demographic data and patients' history of the two parallel groups demonstrated no statistical dierences: in the propiverine group 37 male and 23 female patients with a mean age of 30.3+11.7 years, and in the placebo group 32 male and 21 female patients with an average age of 29.3+10.9 years were included.
Ecacy
The bladder capacity on onset of the ®rst detrusor contraction increased statistically signi®cant by 72 ml under propiverine (V1: 153+107 ml. V2: 224+111 ml) in contrast to 35 ml under placebo (V1: 147+95 ml. V2: 159+107 ml) (P=0.006).
The maximal cystometric bladder capacity increased signi®cantly in the propiverine group, on average by 104 ml (V1: 262+132 ml; V2: 366+143 ml) (P50.0001), in comparison with a decrease under placebo (V1: 296+151 ml; V2: 289+163 ml) ( Figure 1 ).
The maximal detrusor contractions decreased signi®cantly by 27+32 cmH 2 The clinical symptoms assessed by the patients revealed that 63.3% under propiverine were`improved' in comparison with 22.6% under placebo.`Unchanged' symptoms resulted in 16.7% of the patients under verum, in 56.6% under placebo.`Worsening' of symptoms was assessed in 16% of the patients in both of the treatment groups. This assessment is based on the micturition diaries concerning clinical symptoms: the reduction of micturition frequency, enhancement of dry intervals between catheterisations and the achievement of urinary continence, respectively.
Subjective global assessment of ecacy by physicians was`very good' or`good' in 53% of the patients under propiverine but only in 11% of the patients under placebo. In addition, a`satisfactory' ecacy was certi®ed in 25% of the verum group in contrast to 17% of the placebo group.`Insucient' treatment resulted in 18% under propiverine but in 64% under placebo.
Safety
Direct questioning of adverse events yielded incidence rates between 3 and 37% (Table 1) . Twenty-two out of 60 patients in the verum group (37%) and four out of 53 patients in the placebo group (8%) complained of dryness of the mouth. In most of the cases the severity was judged to be mild or moderate under verum as well as under placebo (Figure 3) .
The accommodation disorders were documented as mild in nine, moderate in seven and severe in one case under propiverine, mild in the case of placebo. Nausea, headache, dizziness, tiredness and heart palpitations were reported to be mild or moderate. The vital parameters (blood pressure and heart rate) and the laboratory parameters revealed no changes regarding the comparison of both groups.
Eight drop-outs were registered in the propiverine group (13%; ®ve due to adverse events, three cases without mentioning the underlying reasons) and three in the placebo group (7.5%; one due to adverse events, two cases without mentioning the underlying reasons).
Discussion
The aims of treatment of detrusor hyperre¯exia are the preservation of kidney function and the control of re¯ex urinary incontinence. Preservation of kidney function is surely of prime interest and guarantees a life expectancy almost comparable to non spinal cord injured people. In the presence of detrusor hyperreexia micturition can be achieved either spontaneously once the urine in the bladder reaches re¯ex volume or by trigger mechanisms. Re¯ex voiding is achieved via a sacral re¯ex arch through C-®bre activation. This mostly induces a detrusor ± striated sphincter ± dyssynergia resulting in unbalanced voiding and with the potential danger for the upper urinary tract. The bladder contractions themselves are not sustained and may be hypercontractile but also hypocontractile ± being an additional reason for unbalanced voiding. Triggered re¯ex micturition can only be recommended if the contractility of the detrusor is within normal ranges, if the bladder compliance is normal and bladder emptying balanced. About 25% of patients ful®l these criteria. However, with unphysiological high pressures during the ®lling phase (low compliance) and during the micturition phase, with recurrent urinary Figure 3 Severity of the dryness of the mouth (V2)
Propiverine for detrusor-hyperreflexia M Sto Èher et al tract infections caused by unbalanced voiding, with vesico-ureteral-renal re¯ux or re¯ux into the male adnexe due to a pronounced detrusor-striated sphincter-dyssynergia treatment of detrusor hyper-re¯exia is mandatory. The therapeutic standard now-adays is urinary bladder emptying by (clean) intermittent catheterisation (CIC) and pharmacological treatment of a low compliant and hypercontractile detrusor in order to change the high pressure into a low pressure system. The new generation of smooth muscle relaxant drugs with mixed mode of action: anticholinergic, direct spasmolytic, calcium-channel blocking and local anaesthetic properties, guarantees that hyperre¯exia of the detrusor can be well controlled in the majority of patients, thus preserving the upper urinary tract and enabling continence. 9 The simultaneous increase of residual urine is well accepted in these patients normally emptying their bladder by CIC and in whom the pharmacologically induced detrusor hypocontractility guarantees continence between catherisations. As demonstrated by Yokota et al, 10 anticholinergics are especially eective in the re¯ex bladder as the contribution of cholinergic transmission to detrusor contraction is considerably increased, whereas the purinergic component is decreased in comparison with normals. One must assume that the postganglionic neurotransmission in the re¯ex bladder may be shifted to a cholinergic dominance. This might explain that the eect of these drugs is much more pronounced in detrusor hyperreexia in comparison to detrusor instability. Propiverine possesses strong calcium-antagonistic and moderate anticholinergic-spasmolytic properties as well as analgesic eects. Considering the pharmacological pro®le of propiverine, it might be considered as a special advantage that metabolites with a strong anticholinergic mode of action contribute further to the eects of the parent drug. 2, 3, 11 Increase in maximum cystometric bladder capacity by 30% as well as the decrease of detrusor contractility by more than 40% are comparable to the results achieved with oxybutynin (5 mg t.i.d.) as published by Madersbacher et al. 12 The dosage regimen selected according to the results of a previous dose optimizing study 7 was con®rmed for this indication. The increase in residual urine is comparable to that of oxybutynin, which currently is considered to be the therapeutic standard and which is one of the most commonly used drugs, world-wide accepted in the treatment of detrusor hyperre¯exia. The urodynamic results further document that propiverine also reduces eectively detrusor pressure.
It is generally accepted that with the increase of eectiveness of these drugs, the rate of adverse events also increases. This is also true for dryness of the mouth, one of the most frequent and most bothersome adverse events, manifesting under oxybutynin: ThuÈ ro et al 13 reported 33% of patients with detrusor hyperactivity treated with oxybutynin complaining about dryness of the mouth. Madersbacher et al 12 reported an incidence of 57% in patients with spinal cord injury and detrusur hyperre¯exia treated with oxybutynin 5 mg t.i.d. In 23% this symptom was severe and one of the main reasons for drop-outs. Under propiverine the incidence of dryness of the mouth as well as other adverse events shows a dose dependency as well as a decreasing incidence under long-term treatment. 7, 14 In the present study, the rate of dryness of the mouth is somewhat higher than in spontaneous reports, but lower than in studies with oxybutynin in comparable patient groups. This is in accordance with earlier studies reporting incidence rates of adverse events, especially dryness of the mouth, varying between 19% and 21% under propiverine. The severity was judged in most cases as mild or moderate yielding in a good or very good subjective assessment of tolerability in 61% to 81% of the patients. 5 This clinical study proved the ecacy of propiverine in detrusor hyperre¯exia with regard to the urodynamic parameters of maximal cystometric bladder capacity and detrusor contractility. Increase in residual urine re¯ects the therapeutically desired effect of detrusor relaxation in this special group of patients. Propiverine proved to be an eective and safe drug in the treatment of detrusor hyperre¯exia in spinal cord injured patients.
